New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
How to preserve muscle mass on weight-loss drugs like Wegovy
There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to general weight loss. Is this a real concern, and if so, how can a person maintain their muscle mass on GLP-1 drugs?
Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...
3h
The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...
15hon MSN
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
The NHS has shared its 12 Tips to Help You Lose Weight - and the number one rule completely contradicts the trendy dieting ...
19hon MSN
Millions of Americans would be eligible to have costly weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback